Trial | NCT00170664  Report issue

Title

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    129
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.
Study Started
Jan 31
1999
Primary Completion
Mar 31
2003
Study Completion
Sep 30
2004
Last Update
Mar 25
2016
Estimate

Drug Paclitaxel

Drug Carboplatin

Paclitaxel, Carboplatin Experimental

Criteria 

Inclusion Criteria:

histologically-confirmed epithelial ovarian cancer of FIGO stage IIB - IV
life expectancy of more than three months
ECOG performance status less than 3
laboratory parameters within the normal range, including a glomerular filtration rate (GFR) greater than 60 ml/min, serum creatinine levels below 1.6 mg/dl, liver transaminases less than two times the normal levels, bilirubin concentrations below 1.5 mg/dl, adequate bone marrow function as indicated by a neutrophil count greater than 1,500/µl, and a platelet count greater than 100,000/µl.
written informed consent

Exclusion Criteria:

suffering from secondary malignancy or underlying serious, uncontrolled concurrent medical or psychiatric disease
radiotherapy within 4 weeks for study entry
No Results Posted